MEK inhibitor (specialist)
Binimetinib
Brand names: Mektovi
Adult dose
Dose: 45mg PO BD (with encorafenib)
Route: Oral
Frequency: BD
Clinical pearls
- NICE TA562: BRAF V600 melanoma (with encorafenib)
- ESMO melanoma
- Specialist oncology — BRAF V600 testing
Contraindications
- Pregnancy
- Severe hepatic impairment
- Hypersensitivity
Side effects
- Cardiomyopathy / decreased LVEF
- Pulmonary embolism / DVT
- Retinal pigment epithelial detachment / uveitis
- Hepatotoxicity
- Rhabdomyolysis
- Skin reactions
Interactions
- UGT1A1 inhibitors
Monitoring
- LVEF (echo before, regular)
- LFTs
- Eye review
- Skin
- CK
Reference: BNF; NICE TA562; ESMO; SmPC; https://bnf.nice.org.uk/drugs/binimetinib-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia